Relative vaccine effectiveness of ChAdOx1/AZD1222 vaccines as booster dose via intradermal injection with a one-fifth dose compared with the intramuscular injection in the prevention of SAR-CoV-2 infections in Phuket: A retrospective cohort study.

Autor:	Jangiam W; Samut Sakhon Provincial Public Health Office, Ministry of Public Health, Samut Sakhon, Thailand; Vachira Phuket Hospital, Ministry of Public Health, Phuket, Thailand., Swangpun K; Phuket Provincial Public Health Office, Ministry of Public Health, Phuket, Thailand., Iamsirithaworn S; Department of Disease Control, Ministry of Public Health, Nonthaburi, Thailand., Piriyasatit S; The Gang Technology Co., Ltd., Bangkhae, Bangkok, Thailand., Bhukdee D; The Gang Technology Co., Ltd., Bangkhae, Bangkok, Thailand; Center of Excellence in Computational Molecular Biology, Research Affairs, Faculty of Medicine, Chulalongkorn University, Pathum Wan, Bangkok, Thailand; Center for Artificial Intelligence in Medicine, Research Affairs, Faculty of Medicine, Chulalongkorn University, Pathum Wan, Bangkok, Thailand; Center of Excellence in Cognitive Clinical and Computational Neuroscience, Department of Internal Medicine, Faculty of Medicine, Chulalongkorn University, Pathum Wan, Bangkok, Thailand; International Medical Program, Faculty of Medicine, Chulalongkorn University, Pathum Wan, Bangkok, Thailand. Electronic address: b.dhup@thegang.tech.
Jazyk:	angličtina
Zdroj:	International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases [Int J Infect Dis] 2024 Oct; Vol. 147, pp. 107179. Date of Electronic Publication: 2024 Jul 31.
DOI:	10.1016/j.ijid.2024.107179
Abstrakt:	Objectives: This study assessed the real-world relative vaccine effectiveness of the ChAdOx1/AZD1222 vaccine given intradermally at one-fifth dose compared to the standard intramuscular injection, following the completion of 2 doses of CoronaVac, due to limited vaccine availability in Thailand during the Coronavirus disease 2019 (COVID-19) pandemic. Method: This retrospective cohort study used 138,264 records from Vachira Phuket Hospital, Phuket, Thailand. The records were divided into 2 groups: 49,387 recipients received one-fifth doses via intradermal injections, and 88,877 recipients received standard-dose intramuscular injections from September 14 to October 3, 2021, with follow-up until December 31, 2021. Relative vaccine effectiveness for the cohorts was estimated using Cox regression, adjusting for demographic and clinical risk factors. Results: The adjusted hazard ratio between the intradermal and intramuscular groups was 0.88 (95% Confidence Interval 0.76-1.02, P = 0.09), indicating a nonsignificant protective factor for the intradermal group. Further stratified analysis revealed no significant difference between the 2 groups. The 21 and 28-day postvaccination periods minimized the possibility of confounding due to differences in the cohorts' timeframes. Conclusion: A booster dose of ChAdOx1/AZD1222 given intradermally at one-fifth dose did not show a significant difference compared to the standard intramuscular injection. Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. (Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu